Chippenham, UK: Vectura Group plc, an industry leading inhalation CDMO, today announces that it has signed a global out licence and development agreement with Kinaset Therapeutics Inc. for the development and commercialisation of VR588, a preclinical novel inhaled pan-JAK inhibitor for the prevention and
More
Montelukast is a selective and orally active leukotriene receptor antagonist that inhibits
The U.S. Food and Drug Administration today approved Nucala (mepolizumab) for use
Chippenham, UK: Vectura Group plc, an industry leading inhalation CDMO, today announces that it has signed a global out licence
MoreThe U.S. Food and Drug Administration today approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance treatment
MoreMontelukast is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT4 receptor. Cysteinyl leukotrienes and
More
